Brief: Protagonist Therapeutics Entered Into A License And Collaboration Agreement With Takeda Pharmaceuticals USA

Protagonist Therapeutics

31/01/2024 22:47

Jan 31 (Reuters) - Protagonist Therapeutics Inc
 PTGX.O :
    * PROTAGONIST THERAPEUTICS INC: ENTERED INTO A LICENSE AND
COLLABORATION AGREEMENT WITH TAKEDA PHARMACEUTICALS USA
    * PROTAGONIST THERAPEUTICS INC: AGREEMENT FOR DEVELOPMENT,
MANUFACTURE AND COMMERCIALIZATION OF COMPANY'S RUSFERTIDE AND
OTHER LICENSED PRODUCTS
    * PROTAGONIST THERAPEUTICS: TAKEDA TO PAY CO UPFRONT PAYMENT
OF
$300 MILLION WITHIN 30 DAYS AFTER EFFECTIVE DATE
    * PROTAGONIST THERAPEUTICS: TAKEDA AGREED TO PAY CO TIERED
ROYALTIES OF 10% - 17% ON NET SALES OF LICENSED PRODUCTS IN
TAKEDA TERRITORY
    * PROTAGONIST THERAPEUTICS: PARTIES TO JOINTLY DEVELOP AND
COMMERCIALIZE LICENSED PRODUCTS IN U.S.
    * PROTAGONIST THERAPEUTICS: TAKEDA SOLELY AND EXCLUSIVELY
WILL
DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS IN ALL OTHER
COUNTRIES

Source text for Eikon:  ID:n0001104659-24-008787 
Further company coverage:  PTGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))